SCHEMBL22927013

SCHEMBL22927013

CCOC(=O)c1cnc(OCC)c2ccn(Cc3ccc(Br)cc3)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NPC1 O15118 2/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ RAB9A P51151 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAPT P10636 1/20 0.41
▸ LMNA P02545 2/20 0.40
▸ MAPK1 P28482 2/20 0.40
▸ SMN1; SMN2 Q16637 2/20 0.39
▸ RECQL P46063 1/20 0.39
▸ MAPK10 P53779 1/20 0.39
▸ GAA P10253 3/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ RXFP1 Q9HBX9 1/20 0.39
▸ PDE3B Q13370 1/20 0.39
▸ PDE3A Q14432 1/20 0.39
▸ L3MBTL1 Q9Y468 3/20 0.39
▸ CYP19A1 P11511 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.38
▸ TDP1 Q9NUW8 2/20 0.38
▸ KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21458296 0.94 NPC1 (0.42) NPC1MEN1RAB9AKMT2AMAPT
SCHEMBL26602346 0.90 NPC1 (0.44) NPC1MEN1RAB9AKMT2AMAPT
SCHEMBL21458290 0.89 PKM (0.43) KMT2A
SCHEMBL21458221 0.80 PKM (0.43) MEN1KMT2A
SCHEMBL21458306 0.78 GABRA1 (0.47) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL26606926 0.77 EGLN1 (0.41) MEN1RAB9AKMT2AALDH1A1
SCHEMBL3988625 0.77 GAA (0.49) MEN1KMT2AMAPTLMNASMN1; SMN2
SCHEMBL21506594 0.77 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1
SCHEMBL26602340 0.76 PKM (0.45) MAPTLMNARXFP1
SCHEMBL21506595 0.76 PTGER4 (0.39) MEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11795156-B2 Bicyclic carboxamides and methods of use thereof TEMPEST THERAPEUTICS, INC. (US) 2023-10-24 — — US disclosed
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2023-02-09 — — US disclosed
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF TEMPEST THERAPEUTICS, INC. 2021-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11795156-B2 Bicyclic carboxamides and methods of use thereof PTGER4, PTGER2, CNR2 NPC1 3514/4885MEN1 4314/4885RAB9A 4705/4885
US-20230045612-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 NPC1 3514/4885MEN1 4314/4885RAB9A 4705/4885
US-20210024491-A1 BICYCLIC CARBOXAMIDES AND METHODS OF USE THEREOF PTGER4, PTGER2, CNR2 NPC1 3514/4885MEN1 4314/4885RAB9A 4705/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback